Join to access to all OVN content. Join for Free
The ART of breaking out of your comfort zone
Introversion in MSL overcoming fear in medical science building a personal brand in healthcare networking for introverts success strategies for MSLs

The ART of breaking out of your comfort zone


Share This Article


Summary

In this episode, Cathy Andorfer joins Tom Caravela to discuss the unique challenges and advantages that introverts face within the medical science liaison (MSL) role. They explore the science behind introversion and extroversion, emphasizing the importance of overcoming fear and developing resilience. Cathy shares personal experiences and insights from her upcoming book, offering advice on goal setting, networking, and the significance of building a personal brand while staying authentic. The conversation wraps up with year-end reflections and the importance of being present in one's current role. The episode concludes with closing remarks, future episode teasers, and a reminder to subscribe.

Cathy Andorfer, US Field Medical Dermatology Lead at Bristol Myers Squibb discusses the art of breaking out of your comfort zone

Cathy shares…

πŸ‘‰ The difference between an introvert and an extrovert

πŸ‘‰ How introverts can find success in Medical Affairs

πŸ‘‰ Advice for extroverts on improved engagement

πŸ‘‰ Tips on how to do things that may terrify you

πŸ‘‰ Why “reflection” is so important and how to use it

Click for Source
Introversion in MSL, overcoming fear in medical science, building a personal brand in healthcare, networking for introverts, success strategies for MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN